In clinical trials, the drug was shown to almost double the median survival time for patients with pancreatic cancer.

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...

The new oral medication, daraxonrasib, has been shown to meaningfully extend the lives of patients with late-stage pancreatic ...

A common blood pressure drug may help a major class of cancer therapies work far better than expected. A widely prescribed ...

Merck (MRK.N), opens new tab said on Monday its experimental endometrial cancer drug met the main goals of a late-stage trial ...

Patients — and their doctors — have been desperate for a more effective pancreatic cancer treatment for decades. Now one ...

Doctors are testing a new three-drug treatment that may help patients with cancer whose original source cannot be found.

The FDA said it will grant some patients early access to Revolution Medicines' experimental pancreatic cancer drug daraxonrasib.

Several studies have served up tantalizing hints about the drugs’ potential cancer prevention benefits, but other results ...

A proof-of-concept study has created a blueprint for producing prostate cancer treatment more efficiently. Researchers at the University of Missouri, Cancer Targeted Technology (CTT) and ...

Former Sen. Ben Sasse of Nebraska reveals an experimental cancer drug helped shrink his tumors by 76% after a stage 4 metastatic pancreatic cancer diagnosis.